Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 7INDUSTRY 4NIH 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 2ALK-positive Advanced NSCLC 1ALK+ Advanced NSCLC 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × brigatinib × 1 year × Clear all
NCT05100069 2026-03-17

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Takeda

Recruiting
500 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05721950 2026-02-18

Brilliant

Takeda

Active not recruiting
154 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed
248 enrolled 20 charts
Thoracic

ALK+ Advanced NSCLC

NCT03535740 2025-07-31

ALTA-2

Takeda

Phase 2 Completed
103 enrolled 23 charts
Thoracic

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡